Verdict UNVERIFIED

UNVERIFIED — The FDA approved Casgevy in December 2023, and Casgevy is an oral tablet taken every day, But Not Fully

Verified on July 21, 2026

The FDA approved Casgevy in December 2023 as a landmark gene therapy.

Confidence40%

How strongly independent, cited sources support this verdict.

Claim reviewed

The FDA approved Casgevy in December 2023, and Casgevy is an oral tablet taken every day.

Analysis summary

The FDA approved Casgevy in December 2023 as a landmark gene therapy. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.

Evidence profile

78 / 100 weighted evidence score H:2 / M:0 / L:0

Key findings

  • The FDA approved Casgevy in December 2023 as a landmark gene therapy.

Sources

Analyzed across 2 independent publishers

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease Fda
High credibility 78/100
government_primaryInstitutional domain
Revolutionary breakthrough: FDA approves CASGEVY, the first ... - PMC Nih
High credibility 78/100
government_primaryInstitutional domain

Citations

Copy formatted citations from the verified sources above.

Need to verify another claim?

Open Claims Radar to analyze headlines, posts, or links with live source checks.

Verify a claim
Explore more trending fact checks
Verified by Claims Radar
Possum Mattern Studios